Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 16/20 | 0.64 |
| ▸ | AXL | P30530 | 2/20 | 0.47 |
| ▸ | MERTK | Q12866 | 2/20 | 0.47 |
| ▸ | BCL2 | P10415 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.40 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2014203 | 0.92 | PIK3CD (0.65) | PIK3CDAXLMERTKBCL2MAP4K4 | |
| SCHEMBL12403851 | 0.92 | PIK3CD (0.65) | PIK3CDAXLMERTKBCL2MAP4K4 | |
| SCHEMBL12403852 | 0.92 | PIK3CD (0.65) | PIK3CDAXLMERTKBCL2MAP4K4 | |
| SCHEMBL12631307 | 0.91 | PIK3CD (0.64) | PIK3CDAXLMERTKBCL2MAP4K4 | |
| SCHEMBL2015186 | 0.90 | PIK3CD (0.79) | PIK3CDAXLMERTKBCL2MAP4K4 | |
| SCHEMBL2014116 | 0.90 | PIK3CD (0.65) | PIK3CDAXLMERTKBCL2MAP4K4 | |
| SCHEMBL2016845 | 0.89 | PIK3CD (0.62) | PIK3CDAXLMERTKBCL2MAP4K4 | |
| SCHEMBL2014561 | 0.89 | PIK3CD (0.62) | PIK3CDAXLMERTKBCL2MAP4K4 | |
| SCHEMBL2016212 | 0.85 | PIK3CD (0.77) | PIK3CDAXLMERTKBCL2MAP4K4 | |
| Trifluoroacetic Acid SCHEMBL2163783 | 0.84 | PIK3CD (0.69) | PIK3CDAXLMERTKBCL2PIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680108-B2 | Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2014-03-25 | — | — | US | claimed |
| US-20110183985-A1 | SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2011-07-28 | — | — | US | claimed |
| WO-2011075630-A1 | SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2011-06-23 | — | — | WO | claimed |
| US-8680108-B2 | Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680108-B2 | Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680108-B2 | Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2014-03-25 | — | — | US | disclosed |
| US-20110183985-A1 | SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2011-07-28 | — | — | US | disclosed |
| US-20110183985-A1 | SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2011-07-28 | — | — | US | disclosed |
| US-20110183985-A1 | SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2011-07-28 | — | — | US | disclosed |
| WO-2011075630-A1 | SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2011-06-23 | — | — | WO | disclosed |
| WO-2011075630-A1 | SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183985-A1 | SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS | PIK3R1, PIK3R3, PIK3R2 | PIK3CD 13/4885AXL 508/4885MERTK 1345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.